Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

Black patients chronically infected with genotype 1 hepatitis C virus (HCV) have historically had lower rates of response to interferon‐based treatment than patients of other races. In the phase 3 ION program, the single‐tablet regimen of the NS5A inhibitor ledipasvir and NS5B nucleotide polymerase...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hepatology
Asıl Yazarlar: Wilder, Julius M., Jeffers, Lennox J., Ravendhran, Natarajan, Shiffman, Mitchell L., Poulos, John, Sulkowski, Mark S., Gitlin, Norman, Workowski, Kimberly, Zhu, Yanni, Yang, Jenny C., Pang, Phillip S., McHutchison, John G., Muir, Andrew J., Howell, Charles, Kowdley, Kris, Afdhal, Nezam, Reddy, K. Rajender
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2015
Konular:
Viral Hepatitis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4738375/
https://ncbi.nlm.nih.gov/pubmed/26547499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.28334
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller